Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial

Open access
Kelley, John M., Kaptchuk, Ted J., Cusin, Cristina, Lipkin, Samuel, Fava, Maurizio · 2012 · Psychotherapy and Psychosomatics

Abstract

In randomized controlled trials (RCTs), major depressive disorder (MDD) patients treated with double-blind placebos often show substantial improvement. Indeed, two meta-analyses have estimated that the double-blind placebo response is 80% as large as the double-blind antidepressant response [1,2]. This strong placebo response combined with the absence of side effects has prompted suggestions to use open-label placebo as a first-line treatment for depression [3]. In addition, a recent report on irritable bowel syndrome reported positive findings with open-label placebo [4]. Here we report a pilot study investigating this intriguing question for MDD.We conducted a pilot RCT of open-label placebo in adult outpatients with a primary diagnosis of nonpsychotic MDD as diagnosed by the Structured Clinical Interview for DSM-IV [5]. For the first two weeks, patients were randomized to either open-label placebo or waitlist control. After 2 weeks, participants originally randomized to open-label placebo continued for an additional 2 weeks on open-label placebo, and participants originally assigned to the waitlist control were switched to open-label placebo for an additional 4 weeks, so long as they continued to meet the eligibility requirements after 2 weeks on the waitlist. Patients were instructed to take two placebo pills, twice daily. The placebos were blue capsules containing microcrystalline cellulose.Blinded clinicians assessed patients at baseline and every 2 weeks thereafter. The primary outcome was the clinician-rated 17-item Hamilton Scale for Depression (HAM-D-17) [6]. Secondary, self-report outcomess were the Quick Inventory of Depressive Symptoms (QIDS) [7] and the Symptoms of Depression Questionnaire (SDQ) [8]. The primary test of efficacy was at 2 weeks. The entire sample was used to examine pre-post improvement after 4 weeks of open-label placebo treatment.Prior to randomization, the treating psychiatrists provided all participants with a rationale explaining why open-label placebos might be effective. Following an earlier model [4], the rationale included four points: (a) in RCTs placebos are roughly 80% as effective as antidepressants; (b) classical conditioning is a possible mechanism for automatic self-healing; (c) placebo-treated patients who are more compliant have better outcomes, and therefore the placebos should be taken faithfully, and (d) positive expectations increase placebo effects, but it is OK to have doubts. Although the rationale was scripted, treating psychiatrists were encouraged to deliver the rationale in a natural and supportive manner that allowed for questions and answers. All participants provided written informed consent. Patients were paid USD 20 for each completed assessment, and all patients were offered 3 months of free psychiatric treatment after the trial.Our principal goal was to examine the feasibility of conducting trials of open-label placebo for MDD. Recruitment for this study was the fastest of the ten most recently conducted MDD studies in the Depression Clinic at Massachusetts General Hospital. The mean number of patients screened per month was 4.13 as compared to only 2.55 for the other nine trials. In addition, 75% of patients completed the trial. We recruited a total of 20 patients, primarily women (70%) of middle age (38.8 ± 12.6 years) with moderately severe depression at baseline (mean HAM-D-17 = 18.0 ± 4.9). There were no significant differences between the open-label placebo (n = 11) and waitlist control (n = 9) groups on demographics or baseline severity.At the two-week endpoint, there were no statistically significant differences between open-label placebo and waitlist, and the observed symptom improvement was relatively small compared with typical MDD RCTs (table 1a). On the other hand, the effect size for the main outcome measure (HAM-D-17) was medium (d = 0.54), which is larger than typical effect sizes for the drug-placebo difference in MDD RCTs [1] and above the criterion for a clinically significant improvement set by the National Institute for Clinical Excellence (NICE) in the UK [9]. In addition, there were statistically significant pre-post improvements on all three outcome measures after 4 weeks of open-label placebo treatment, with moderate to large effect sizes (table 1b). However, improvement on the HAM-D-17 was relatively small as compared to the improvement typically seen in MDD RCTs.To our knowledge, this is the first RCT to test the efficacy of open-label placebo for MDD. Despite the fact that we observed a medium-sized effect for the main outcome measure, our findings do not support the hypothesis that open-label placebo is effective for MDD. However, the results were in the predicted direction, and this pilot study was limited by the small sample size, low statistical power, and short duration.An important question that might be raised is whether this study tests open-label placebo or the power of suggestion of the rationale. Critics

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000337053

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 190

Metadata

Authors
Kelley, J. M., Kaptchuk, T. J., Cusin, C., Lipkin, S., & Fava, M.
Venue
Psychotherapy and Psychosomatics
Publisher
S. Karger AG
Published
2012
Volume
81
Issue
5
Pages
312-314
ISSN
  • 0033-3190 (ISSN-L)
  • 1423-0348
OpenAlex
W2089653610
Cited by
190
References
3
FWCI
3.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.